Survodutide vs Retatrutide: Dual vs Triple Agonist

Survodutide and retatrutide are both investigational obesity drugs that add glucagon to GLP-1, but retatrutide goes a step further by also targeting GIP. Neither is FDA approved or available, from TrimRx or anywhere else, as of mid-2026. Retatrutide has produced more weight loss in trials (~28% versus survodutide’s ~15 to 19%), while survodutide has stood out for a different reason: unusually strong results in fatty liver disease. Here is how the dual agonist and the triple agonist compare.

Dual vs triple: the core difference

Both drugs share two mechanisms: GLP-1 (appetite) and glucagon (energy expenditure and liver fat metabolism). The difference is that retatrutide adds a third, GIP, a second incretin hormone that may improve how the body handles fat and can ease nausea compared with GLP-1 alone. Survodutide sticks with two.

Weight loss: retatrutide is ahead

On the scale, retatrutide leads. Its Phase 3 trials have produced about 28% average weight loss. Survodutide’s Phase 2 obesity trial produced about 15% at 46 weeks at the top dose, with the weight-loss curve still falling at the end of the study, which hints that longer treatment might push the number higher. Survodutide is now in Phase 3, so larger and longer data are coming.

As always with cross-trial comparisons, the gap is directional, not a head-to-head verdict. But retatrutide’s triple mechanism has consistently produced the highest weight-loss figures in the field.

Survodutide’s edge: the liver

Where survodutide stands out is not weight, but the liver. In a Phase 2 trial in people with metabolic dysfunction-associated steatohepatitis (MASH, a serious fatty liver disease), a majority of participants on higher doses had their liver disease resolve, far more than on placebo, along with meaningful improvement in liver scarring (fibrosis). Those are among the stronger liver results reported for this class, and they may lead survodutide’s path to approval, potentially for MASH alongside or even ahead of obesity.

Retatrutide also reduces liver fat (the glucagon component helps with that), but survodutide’s MASH data has been its signature result. For context, the GLP-1 class as a whole is increasingly studied for fatty liver disease, and even approved drugs like semaglutide have shown liver benefits.

Timeline and availability

Both drugs are investigational and in Phase 3. Neither is FDA approved, neither can be prescribed or compounded, and neither is available from TrimRx. Retatrutide’s FDA application is expected around late 2026; survodutide is earlier in its Phase 3 program, with timelines that depend on its obesity and MASH trials reading out. Realistic availability for either is 2027 at the earliest.

Any survodutide or retatrutide sold online now is not legitimate, and research-grade peptides lack the quality, sterility, and dosing oversight of approved medications.

Side effects

Both share a glucagon-driven profile, which means both can modestly raise resting heart rate, something their cardiovascular trials are evaluating. Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common for both and tend to cluster during dose escalation. Retatrutide’s added GIP component may help tolerability somewhat, though direct comparisons are not available.

Which is more promising?

Consider a scenario where someone is weighing these two for the future. They are aimed at somewhat different priorities: retatrutide for maximum weight loss, survodutide for a combination of weight loss and liver disease. Neither is available, so the practical decision today is not between them. It is whether to start an approved, available medication now. Approved drugs like tirzepatide and semaglutide already produce substantial weight loss as regulated, prescribed products, and they are options you can actually begin.

You can check whether an approved program fits your goals through a quick assessment, and follow survodutide and retatrutide as their larger trials report.

This article is for educational purposes only and is not medical advice. Survodutide and retatrutide are investigational drugs that are not FDA approved and are not available by prescription or through compounding; the figures described come from separate clinical trials, not from real-world use. Never use research-grade or grey-market peptides as a substitute for an approved medication, and always consult a licensed healthcare provider before starting, stopping, or changing any treatment.